CSPC announced that the SYH2085 tablets developed by the Group have been approved by the State Drug Administration of the People's Republic of China and can conduct clinical trials in China. This product is an innovative chemical class 1 drug independently developed by the Group. It is a novel oral small molecule drug candidate that can inhibit the activity of RNA polymerase acid protein endonuclease in the influenza virus. The clinical indications approved this time are for the treatment of simple influenza A and B in adults and adolescents aged 12 and above.

CSPC announced that the SYH2085 tablets developed by the Group have been approved by the State Drug Administration of the People's Republic of China and can conduct clinical trials in China. This product is an innovative chemical class 1 drug independently developed by the Group. It is a novel oral small molecule drug candidate that can inhibit the activity of RNA polymerase acid protein endonuclease in the influenza virus. The clinical indications approved this time are for the treatment of simple influenza A and B in adults and adolescents aged 12 and above.